179 related articles for article (PubMed ID: 37810895)
1. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
2. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
3. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
Claimon A; Pusuwan P; Khiewvan B
J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
[TBL] [Abstract][Full Text] [Related]
5. Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China.
Liu Q; Yin M; Li G
Front Endocrinol (Lausanne); 2021; 12():774275. PubMed ID: 34975751
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
Zhao Y; Mu Z; Liang D; Zhang T; Zhang X; Sun D; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2024; 15():1354426. PubMed ID: 38721144
[TBL] [Abstract][Full Text] [Related]
7. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
8. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
10. Effect of Lymph Node Metastasis on Change of Positive Thyroglobulin Antibody in Differentiated Thyroid Carcinoma after Initial Treatment.
Zhang T; Song LP; Zhao T; Gao W; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):539-543. PubMed ID: 28877833
[TBL] [Abstract][Full Text] [Related]
11. Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic
Li X; Li H; Yan Y; Xu H; Wang Y; Liu Y; Gao R
Endocrine; 2023 Oct; 82(1):117-125. PubMed ID: 37209260
[TBL] [Abstract][Full Text] [Related]
12. Stimulated serum thyroglobulin but not RAIU level is a prognostic factor for ablation efficacy with a 3.7GBq (100mCi) fixed
Xiao L; Wang Y; Huang R; Li L
Hell J Nucl Med; 2021; 24(1):53-59. PubMed ID: 33866339
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
14. Thyroglobulin antibodies: Trend over time and clinical impact in differentiated thyroid carcinoma with and without radioiodine ablation.
Iglesias ML; Calabretta JM; Coggiola O; Califano I
Endocrinol Diabetes Nutr (Engl Ed); 2022 Nov; 69(9):702-708. PubMed ID: 36470645
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
16. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation.
Chung JK; Park YJ; Kim TY; So Y; Kim SK; Park DJ; Lee DS; Lee MC; Cho BY
Clin Endocrinol (Oxf); 2002 Aug; 57(2):215-21. PubMed ID: 12153600
[TBL] [Abstract][Full Text] [Related]
18. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
19. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
20. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
